Ipilimumab (an anti- CTLA-4 immunotherapy for advanced melanoma) and fotemustine (a chemotherapy for melanoma with cerebral metastases) are the only two drugs that could be individualised, as these are the only two treatments of advanced melanoma documented in the FICHCOMP database. The gene discussed is CTLA4; the disease is melanoma.